Prognostic Relevance of Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2006-2008

ABSTRACT

The purpose of this study is to determine whether early recurrence after curative resection of ductal pancreatic adenocarcinoma can be explained by either dissemination of cancer cells during intraoperative tumour manipulation, post-operative systemic immune suppression, alteration of biological properties of circulating cancer cells or a combination of these. Detailed Description Prognostic relevance of circulating cancer cells and immunosuppression in resectable pancreatic carcinoma 1. Introduction Pancreatic adenocarcinoma is the fourth commonest cause of death from cancer in men and women, with 5-year survival for all stages of disease of less than 5%. The case-fatality rate for pancreatic cancer is extremely high and virtually identical to the number of new cases (World Health Organization. World cancer report. Lyon: IACR Press; 2003). Most patients with cancer of the pancreas are diagnosed at an advanced stage and have a median survival of 4 to 10 months, depending on the extent of disease and irrespective the type of treatment modality. Overall, fewer than 5% of the patients have resection with curative intent, though over 80% will develop cancer recurrence (Jemal A, Thomas A, Murray T, Thun M. Cancer Statistics. CA Cancer J Clin 2002; 52: 23-47). The primary site of metastatic disease in patients with pancreatic cancer is the liver and/or the peritoneal cavity. Cancer recurrence is multifactorial and determined by patient-, tumour-, and surgery-related factors. Any combination of several mechanisms have been proposed by which cancer may recur following potentially curative resection (Coffey JC, Wang JH, Smith MJF, Bouchier-Hayes D, Cotter TG,and Redmond HP. Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol 2003;4:760-68). Surgery may contribute to the overall residual tumor burden by adding disseminated cancer cells during tumor manipulation. Due to post-operative immunosuppression the patient may become more susceptible to tumorigenesis and/or disseminated cancer cells may escape the immune response more easily. Finally, surgical resection may alter biological properties of cancer cells and lead to increased cellular proliferation and reduced cell death. 2. Cancer cell dissemination Solid markers are lacking to predict cancer recurrence or cancer progression before being measurable with conventional or modern diagnostic imaging. Molecular techniques such as the reverse transcriptase polymerase chain reaction (RT-PCR) technique have proven to be a highly sensitive method and a powerful tool in the study of cancer metastasis (Raj GV, Moreno JG, Gomella LG. Utilization of Polymerase Chain Reaction Technology in the Detection of Solid Tumors. Cancer 1998; 82: 1419-42). The prognostic relevance of circulating cancer cells in patients with pancreatic cancer is hardly studied. In patients with breast cancer the number of circulating cancer cells expressing EpCAM (epithelial cell adhesion molecule) has proven to be an independent predictor of progression-free and overall survival (Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-91). EpCAM is a marker present on most epithelial cell tumours and frequently overexpressed in primary and metastatic adenocarcinoma including pancreatic cancer (Rao CG, Chianese D, Doyle GV, Miller MC, Russell T, Sanders RA Jr, Terstappen LW. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol 2005; 27: 49-57). Also, other markers such as CEA, CK20, K-ras have been used to detect disseminated pancreatic cancer cells. In patients with colorectal carcinoma circulating cancer cells in peripheral or in mesenteric venous blood as detected by RT-PCR, using CEA and CK20 mRNA transcripts, seem to represent a prognostic factor (Yamaguchi K, Takagi Y, Aoki S, Futamura M, Saji S. Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann Surg 2000; 232: 58-65. Guller U, Zajac P, Schnider A, Bösch B, Vorburger S, Zuber M, Spagnoli GC, Oertli D, Maurer R, Metzger U, Harder F, Heberer M, Marti WR. Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg 2002; 236: 768-76). 3. Molecular characteristics of metastatic cancer cells The development of metastasis is a highly selective process favoring the survival of a minor subpopulation of metastatic cells. To produce metastases, tumor cells from this subpopulation must complete a sequence of interrelated steps. To produce clinically relevant distant metastases, the successful metastatic cell must therefore exhibit a complex phenotype that is regulated by transient or permanent changes at the gene level. Many malignant tumors, including pancreatic cancer, contain heterogeneous subpopulations of cells. This heterogeneity is exhibited in a wide range of genetic, biochemical, immunological, and biological characteristics such as growth rate, antigenic and immunogenic status, cell surface receptors and products, enzymes, karyotypes, cell morphologies, invasiveness, drug resistance, and metastatic potential. It is likely that specific tumor cells or colonies within the larger heterogeneous tumor specimen are the forerunners of distant metastases. The overall efficiency of the whole metastatic process itself is low. Although the absolute number of cancer cells required for metastasis in humans is unknown, a positive relationship between the number of circulating cancer cells and the subsequent development of metastases has been the subject of several experimental studies (Fisher, E.R. and Fisher, B. Experimental study of factors influencing development of hepatic metastases from circulating tumor cells. Acta Cytol. 9: 146-159, 1965. Fidler, I.J. The relationship of embolic homogeneity, number, size and viability to the incidence of experimental metastasis. Europ. J. Cancer 9: 223-227, 1973. Liotta, L.A., Kleinerman, J., Saidel, G. Quantitative relationships of intravascular tumor cells, tumor vessels and pulmonary metastasis. Cancer Res. 34: 977-1004, 1974. Weiss, L., Mayhew, E., Glaves, R.P. and Holmes, J.C. Metastatic inefficiency in mice bearing B16 melanomas. Br. J. Cancer 45: 44-53, 1982. Topal B, Aerts JL, Roskams T, Fieuws S, Van Pelt J, Vandekerckhove P, Penninckx F. Cancer cell dissemination during curative surgery for colorectal liver metastases. Eur J Surg Oncol 2005; 31: 506-511). The poor prognosis and lack of effective treatments for pancreatic cancer arise from several causes. There are currently no effective biomarkers useful for early detection of pancreatic cancer that tends to rapidly invade surrounding structures and undergo early metastatic spreading. Moreover, pancreatic cancer is highly resistant to both chemotherapy and radiation therapy. Currently, the molecular basis for these characteristics is unknown. Gene expression profiles provide important information about the molecular characteristics of the cancers and can be used to distinguish closely related cancer subtypes. Gene profiling can also be used to develop candidate biomarkers and to identify groups of genes involved in specific functional aspects of tumor biology. Gene expression profiles that could distinguish between pancreatic tumors, chronic pancreatitis and normal pancreatic tissue have been studied extensively using different microarrays and microarray platforms. The differentially expressed genes in pancreatic tumor tissues were found to be quite specific and highly reproducible among platforms and studies (Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, Loader J, Terris B, Stamp G, Baron A, Scarpa A and Lemoine NR. Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 2002; 21: 4587-4594. Han H, Bearss DJ, Browne LW, Calaluce R, Naagle RB, Von Hoff DD. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 2002; 62: 2890-96. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, Adsay NV, Shen-Ong GL, Berg K, Hollingsworth MA, Cameron JL, Yeo CJ, Kern SE, Goggins M, Hruban RH. Cancer Res 2003; 63: 8614-22. Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, Misek DE, Hanash S. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 2003; 63: 2649-57). 4. Peri-operative immunological changes Suppression of the immune system is a feature of the post-operative stress response, in which natural killer (NK) and lymphocyte activated killer (LAK) cells form an integral component in immune anti-tumor surveillance. However, a tumor type-specific immune reaction in pancreatic cancer or in patients undergoing surgery is lacking. Anti-tumoral activities of NK and LAK cells are reduced immediately after surgery so the additive effects of surgery may be sufficient to improve the ability of disseminated cancer cells to evade the host immune response long enough for metastases to develop (Da Costa ML, Finnegan N, Flynn M, Bouchier-Hayes DJ. Laparotomy and laparoscopy differentially accelerate experimental flank tumourgrowth. Br J Surg 1998; 85: 1439-42.) (Da Costa ML, Redmond HP, Bouchier-Hayes DJ. The effect of laparotomy and laparoscopy on the establishment of spontaneous tumour metastases. Surgery 1998; 124: 516-26). The suppressive immunological changes that follow surgical stress occur along a temporal pattern. Depression of cellular immunity to tumor-associated antigen and depression of delayed-type hypersensitivity are present for up to 3 weeks after surgery. In patients with pancreatic cancer the prevalence of regulatory T cells (Treg) is increased in the peripheral blood as well as in the tumour microenvironment. These Treg cells (CD4+25+) are phenotypically similar to Treg cells from normal donors by coexpression of CD45R0 and CTLA-4 molecules as well as cytokine profile. Regulatory CD4+25+ lymphocytes infiltrate tumor and regional lymph nodes, and suppress activation of CD8+ lymphocytes and helper CD4+25- lymphocytes (Liyanage, U. K., T. T. Moore, H. G. Joo, Y. Tanaka, V. Herrmann, G. Doherty, J. A. Drebin, S. M. Strasberg, T. J. Eberlein, P. S. Goedegebuure, and D. C. Linehan. 2002. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756). However, the oncological significance of changes in activities and numbers of NK, LAK, Treg and dendritic cells still has to be confirmed. 5. Aims / Endpoints - Is the number of circulating cancer cells a determinant for cancer recurrence and/or survival following potentially curative resection of pancreatic cancer? - Is the genetic profile of circulating cancer cells a determinant for cancer recurrence and/or survival following potentially curative resection of pancreatic cancer? - Is peri-operative immunosuppression correlated with cancer recurrence and/or survival following potentially curative resection of pancreatic cancer? 6. Patient selection and inclusion criteria: Potentially curable/ resectable pancreatic cancer 7. Study interventions - Quantitative analysis of circulating cancer cells In the present study peripheral venous blood samples will be obtained before the start of surgery, at the end of surgery, on the first day after and on day 7 after surgery through a central venous catheter. Tumour tissue samples and random liver tru-cut biopsies will be obtained intra-operatively. Real-time quantitative RT-PCR technique (TaqManR), based on 3 different target markers (CEA, CK20 and EpCAM mRNA transcripts) and beta-glucuronidase (GUS) as control gene, will be used to detect and quantify circulating cancer cells in the blood stream. Normalized copy numbers (NCN) will be determined in each sample (analyzed in duplicate). RNA extraction from all samples will be performed using RNeasy mini kit(Qiagen, BD Company). Sample preparation, cDNA synthesis and PCR will be performed in separated rooms in order to prevent cross-contamination. - Genetic profiling of disseminated cancer cells Oligonucleotide microarray analysis of mRNA extracted from the primary pancreatic tumor and from disseminated cancer cells before, during and the day after surgery. The focus of this study is not to identify specific markers for diagnosis or for drug targets but to find indications of metastasis through the study of gene expression in cancer cells circulating in the bloodstream. Our main objective is to analyze expression profiles of circulating pancreatic cancer cells. Changes will be analyzed in the expression of genes representative of several different pathways frequently altered during the progression of cancer such as tumor suppressors, oncogenes, signal transduction molecules, growth factors and angiogenesis factors. Gene expression profile data will be obtained on apoptosis, cell cycle, cell growth and differentiation, cell migration and motility, signal transduction and other cancer-related genes. Latest developments in microarray technology comprise the manufacturing of the complete genome and in designing new amplification strategies to be able to analyze very small samples less than 1 ng total RNA (Xiang CC, Chen M, Kozhich OA, Phan QN, Inman JM, Chen Y, Brownstein MJ. Probe generation directly from small number of cells for DNA microarray studies. Biotechniques 2003; 34: 386-8, 390, 392-3. Schindler H, Wiese A, Auer J, Burtscher H. cRNA target preparation for microarrays: comparison of gene expression profiles generated with different amplification procedures. Anal Biochem 2005; 344: 92-101. Puskás LG, Zvara Á, Hackler L Jr, Van Hummelen P. RNA amplification results in reproducible microarray data with slight ratio bias. Biotechniques 2002; 32: 1330-1341). In the present study the number of cancer cells circulating in the blood stream is expected to be extremely small. Therefore, linear RNA amplification (T7 RNA-polymerase) is used in order to generate enough material for labeling and hybridization on the arrays. Two rounds of amplification are performed routinely. This has been performed successfully and reproducibly starting from as little as 700 cells isolated via Laser Capture Microdissection (data unpublished). - Preparation of cell suspension microarrays to isolate circulating cancer cells. Although most of the microarray challenges are known and under control, the present study has an important specific challenge that is the isolation and enrichment of the circulating cancer cells. Currently, the proportion of circulating cancer cells to other nucleated blood cells (leucocytes) is unknown in patients suffering from pancreatic cancer. Therefore, the first step will be to determine the number of cancer cells per ml blood in pancreatic cancer patients and to determine the variability among different patients. A second step is to develop an enrichment method to concentrate the cancer cells without selecting specific types of cancer cells or loss of information on the initial proportion of cancer cells in each patient's blood stream. The fastest way to isolate the circulating cancer cells is using flow cytometry after density-gradient pre-enrichment in combination with negative selection strategies to discard leukocytes (CD45+ and CD34+) from the sorted 'circulating' cancer cells. Isolating cells with LCM has been used many times successfully for microarray studies. It has been reported that LCM can easily dissect several thousands of cells from pancreatic tissue with a RNA-yield of around 1ng/1000 cells (Datson NA, Meijer L, Steenbergen PJ. Morsiak MC, van der Laan S, Meijer OC, de Kloet ER. Expression profiling in laser-microdissected hippocampal subregions in rat brain reveals large subregion specific differences in expression. Eur J Neurosci 2004; 20: 2541-54. Player A, Barrett JC, Kawasaki ES. Laser capture microdissection, microarrays and the precise definition of a cancer cell. Expert Rev Mol Diagn 2004; 4: 831-40. Espina V, Geho D, Mehta AI, Petricoin EF 3rd, Liotta LA, Rosenblatt KP. Pathology of the future: molecular profiling for targeted therapy. Cancer Invest 2005; 23: 36-46. Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, Loader J, Terris B, Stamp G, Baron A, Scarpa A and Lemoine NR. Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 2002; 21: 4587-4594). - Immunological changes Since a tumor type-specific immune reaction in pancreatic cancer or in patients undergoing surgery is lacking, the present study will assess the systemic immunological changes including cytokine levels before and at different time intervals following potentially curative surgery in pancreatic cancer patients. PBMC will be extracted from peripheral venous blood and used for further analysis under FACS (fluorescence-activated cell sorter) to determine the prevalence of: - CD3-19+ (B-lymphocytes) - CD3+56+ (Killer cells) - CD3-56+CD16+ (NK natural killer cells) - CD8+ (Cytotoxic T-lymphocytes) - CD4+25- (Helper T-lymphocytes) - CD4+25+127- (Regulatory T-lymphocytes) - Inflammatory cytokines in peripheral blood (IL-1b, IL-6, IL-8, IL-10, IL-12 and TNF) will be analysed using a commercially available 'BD Cytometric Bead Array (CBA) Human Inflammatory Kit'. - PBMC (peripheral blood mononuclear cells) and tumour tissue will be stored in liquid nitrogen for analysis in future studies. 8. Statistical analysis Univariate analysis as well as corrected, multivariate analysis will be performed in order to identify the optimally combined prognostic group of factors: patient-, tumour-, and treatment-associated factors as well as the amounts of disseminated cancer cells, their genetic expression profile and immunological changes following surgery. The events to study will be cancer recurrence (disease free survival DFS) and death (overall survival OS). 9. Expected patient accrual "Single center study": UZ.Gasthuisberg - KU.Leuven, Belgium Expected annual patient registration: 30 pts / year Duration of patient accrual: 2 years More... »

URL

https://clinicaltrials.gov/show/NCT00495924

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The purpose of this study is to determine whether early recurrence after curative resection of ductal pancreatic adenocarcinoma can be explained by either dissemination of cancer cells during intraoperative tumour manipulation, post-operative systemic immune suppression, alteration of biological properties of circulating cancer cells or a combination of these.\n\nDetailed Description\nPrognostic relevance of circulating cancer cells and immunosuppression in resectable pancreatic carcinoma 1. Introduction Pancreatic adenocarcinoma is the fourth commonest cause of death from cancer in men and women, with 5-year survival for all stages of disease of less than 5%. The case-fatality rate for pancreatic cancer is extremely high and virtually identical to the number of new cases (World Health Organization. World cancer report. Lyon: IACR Press; 2003). Most patients with cancer of the pancreas are diagnosed at an advanced stage and have a median survival of 4 to 10 months, depending on the extent of disease and irrespective the type of treatment modality. Overall, fewer than 5% of the patients have resection with curative intent, though over 80% will develop cancer recurrence (Jemal A, Thomas A, Murray T, Thun M. Cancer Statistics. CA Cancer J Clin 2002; 52: 23-47). The primary site of metastatic disease in patients with pancreatic cancer is the liver and/or the peritoneal cavity. Cancer recurrence is multifactorial and determined by patient-, tumour-, and surgery-related factors. Any combination of several mechanisms have been proposed by which cancer may recur following potentially curative resection (Coffey JC, Wang JH, Smith MJF, Bouchier-Hayes D, Cotter TG,and Redmond HP. Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol 2003;4:760-68). Surgery may contribute to the overall residual tumor burden by adding disseminated cancer cells during tumor manipulation. Due to post-operative immunosuppression the patient may become more susceptible to tumorigenesis and/or disseminated cancer cells may escape the immune response more easily. Finally, surgical resection may alter biological properties of cancer cells and lead to increased cellular proliferation and reduced cell death. 2. Cancer cell dissemination Solid markers are lacking to predict cancer recurrence or cancer progression before being measurable with conventional or modern diagnostic imaging. Molecular techniques such as the reverse transcriptase polymerase chain reaction (RT-PCR) technique have proven to be a highly sensitive method and a powerful tool in the study of cancer metastasis (Raj GV, Moreno JG, Gomella LG. Utilization of Polymerase Chain Reaction Technology in the Detection of Solid Tumors. Cancer 1998; 82: 1419-42). The prognostic relevance of circulating cancer cells in patients with pancreatic cancer is hardly studied. In patients with breast cancer the number of circulating cancer cells expressing EpCAM (epithelial cell adhesion molecule) has proven to be an independent predictor of progression-free and overall survival (Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-91). EpCAM is a marker present on most epithelial cell tumours and frequently overexpressed in primary and metastatic adenocarcinoma including pancreatic cancer (Rao CG, Chianese D, Doyle GV, Miller MC, Russell T, Sanders RA Jr, Terstappen LW. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol 2005; 27: 49-57). Also, other markers such as CEA, CK20, K-ras have been used to detect disseminated pancreatic cancer cells. In patients with colorectal carcinoma circulating cancer cells in peripheral or in mesenteric venous blood as detected by RT-PCR, using CEA and CK20 mRNA transcripts, seem to represent a prognostic factor (Yamaguchi K, Takagi Y, Aoki S, Futamura M, Saji S. Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann Surg 2000; 232: 58-65. Guller U, Zajac P, Schnider A, B\u00f6sch B, Vorburger S, Zuber M, Spagnoli GC, Oertli D, Maurer R, Metzger U, Harder F, Heberer M, Marti WR. Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg 2002; 236: 768-76). 3. Molecular characteristics of metastatic cancer cells The development of metastasis is a highly selective process favoring the survival of a minor subpopulation of metastatic cells. To produce metastases, tumor cells from this subpopulation must complete a sequence of interrelated steps. To produce clinically relevant distant metastases, the successful metastatic cell must therefore exhibit a complex phenotype that is regulated by transient or permanent changes at the gene level. Many malignant tumors, including pancreatic cancer, contain heterogeneous subpopulations of cells. This heterogeneity is exhibited in a wide range of genetic, biochemical, immunological, and biological characteristics such as growth rate, antigenic and immunogenic status, cell surface receptors and products, enzymes, karyotypes, cell morphologies, invasiveness, drug resistance, and metastatic potential. It is likely that specific tumor cells or colonies within the larger heterogeneous tumor specimen are the forerunners of distant metastases. The overall efficiency of the whole metastatic process itself is low. Although the absolute number of cancer cells required for metastasis in humans is unknown, a positive relationship between the number of circulating cancer cells and the subsequent development of metastases has been the subject of several experimental studies (Fisher, E.R. and Fisher, B. Experimental study of factors influencing development of hepatic metastases from circulating tumor cells. Acta Cytol. 9: 146-159, 1965. Fidler, I.J. The relationship of embolic homogeneity, number, size and viability to the incidence of experimental metastasis. Europ. J. Cancer 9: 223-227, 1973. Liotta, L.A., Kleinerman, J., Saidel, G. Quantitative relationships of intravascular tumor cells, tumor vessels and pulmonary metastasis. Cancer Res. 34: 977-1004, 1974. Weiss, L., Mayhew, E., Glaves, R.P. and Holmes, J.C. Metastatic inefficiency in mice bearing B16 melanomas. Br. J. Cancer 45: 44-53, 1982. Topal B, Aerts JL, Roskams T, Fieuws S, Van Pelt J, Vandekerckhove P, Penninckx F. Cancer cell dissemination during curative surgery for colorectal liver metastases. Eur J Surg Oncol 2005; 31: 506-511). The poor prognosis and lack of effective treatments for pancreatic cancer arise from several causes. There are currently no effective biomarkers useful for early detection of pancreatic cancer that tends to rapidly invade surrounding structures and undergo early metastatic spreading. Moreover, pancreatic cancer is highly resistant to both chemotherapy and radiation therapy. Currently, the molecular basis for these characteristics is unknown. Gene expression profiles provide important information about the molecular characteristics of the cancers and can be used to distinguish closely related cancer subtypes. Gene profiling can also be used to develop candidate biomarkers and to identify groups of genes involved in specific functional aspects of tumor biology. Gene expression profiles that could distinguish between pancreatic tumors, chronic pancreatitis and normal pancreatic tissue have been studied extensively using different microarrays and microarray platforms. The differentially expressed genes in pancreatic tumor tissues were found to be quite specific and highly reproducible among platforms and studies (Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, Loader J, Terris B, Stamp G, Baron A, Scarpa A and Lemoine NR. Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 2002; 21: 4587-4594. Han H, Bearss DJ, Browne LW, Calaluce R, Naagle RB, Von Hoff DD. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 2002; 62: 2890-96. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, Adsay NV, Shen-Ong GL, Berg K, Hollingsworth MA, Cameron JL, Yeo CJ, Kern SE, Goggins M, Hruban RH. Cancer Res 2003; 63: 8614-22. Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, Misek DE, Hanash S. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 2003; 63: 2649-57). 4. Peri-operative immunological changes Suppression of the immune system is a feature of the post-operative stress response, in which natural killer (NK) and lymphocyte activated killer (LAK) cells form an integral component in immune anti-tumor surveillance. However, a tumor type-specific immune reaction in pancreatic cancer or in patients undergoing surgery is lacking. Anti-tumoral activities of NK and LAK cells are reduced immediately after surgery so the additive effects of surgery may be sufficient to improve the ability of disseminated cancer cells to evade the host immune response long enough for metastases to develop (Da Costa ML, Finnegan N, Flynn M, Bouchier-Hayes DJ. Laparotomy and laparoscopy differentially accelerate experimental flank tumourgrowth. Br J Surg 1998; 85: 1439-42.) (Da Costa ML, Redmond HP, Bouchier-Hayes DJ. The effect of laparotomy and laparoscopy on the establishment of spontaneous tumour metastases. Surgery 1998; 124: 516-26). The suppressive immunological changes that follow surgical stress occur along a temporal pattern. Depression of cellular immunity to tumor-associated antigen and depression of delayed-type hypersensitivity are present for up to 3 weeks after surgery. In patients with pancreatic cancer the prevalence of regulatory T cells (Treg) is increased in the peripheral blood as well as in the tumour microenvironment. These Treg cells (CD4+25+) are phenotypically similar to Treg cells from normal donors by coexpression of CD45R0 and CTLA-4 molecules as well as cytokine profile. Regulatory CD4+25+ lymphocytes infiltrate tumor and regional lymph nodes, and suppress activation of CD8+ lymphocytes and helper CD4+25- lymphocytes (Liyanage, U. K., T. T. Moore, H. G. Joo, Y. Tanaka, V. Herrmann, G. Doherty, J. A. Drebin, S. M. Strasberg, T. J. Eberlein, P. S. Goedegebuure, and D. C. Linehan. 2002. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756). However, the oncological significance of changes in activities and numbers of NK, LAK, Treg and dendritic cells still has to be confirmed. 5. Aims / Endpoints - Is the number of circulating cancer cells a determinant for cancer recurrence and/or survival following potentially curative resection of pancreatic cancer? - Is the genetic profile of circulating cancer cells a determinant for cancer recurrence and/or survival following potentially curative resection of pancreatic cancer? - Is peri-operative immunosuppression correlated with cancer recurrence and/or survival following potentially curative resection of pancreatic cancer? 6. Patient selection and inclusion criteria: Potentially curable/ resectable pancreatic cancer 7. Study interventions - Quantitative analysis of circulating cancer cells In the present study peripheral venous blood samples will be obtained before the start of surgery, at the end of surgery, on the first day after and on day 7 after surgery through a central venous catheter. Tumour tissue samples and random liver tru-cut biopsies will be obtained intra-operatively. Real-time quantitative RT-PCR technique (TaqManR), based on 3 different target markers (CEA, CK20 and EpCAM mRNA transcripts) and beta-glucuronidase (GUS) as control gene, will be used to detect and quantify circulating cancer cells in the blood stream. Normalized copy numbers (NCN) will be determined in each sample (analyzed in duplicate). RNA extraction from all samples will be performed using RNeasy mini kit(Qiagen, BD Company). Sample preparation, cDNA synthesis and PCR will be performed in separated rooms in order to prevent cross-contamination. - Genetic profiling of disseminated cancer cells Oligonucleotide microarray analysis of mRNA extracted from the primary pancreatic tumor and from disseminated cancer cells before, during and the day after surgery. The focus of this study is not to identify specific markers for diagnosis or for drug targets but to find indications of metastasis through the study of gene expression in cancer cells circulating in the bloodstream. Our main objective is to analyze expression profiles of circulating pancreatic cancer cells. Changes will be analyzed in the expression of genes representative of several different pathways frequently altered during the progression of cancer such as tumor suppressors, oncogenes, signal transduction molecules, growth factors and angiogenesis factors. Gene expression profile data will be obtained on apoptosis, cell cycle, cell growth and differentiation, cell migration and motility, signal transduction and other cancer-related genes. Latest developments in microarray technology comprise the manufacturing of the complete genome and in designing new amplification strategies to be able to analyze very small samples less than 1 ng total RNA (Xiang CC, Chen M, Kozhich OA, Phan QN, Inman JM, Chen Y, Brownstein MJ. Probe generation directly from small number of cells for DNA microarray studies. Biotechniques 2003; 34: 386-8, 390, 392-3. Schindler H, Wiese A, Auer J, Burtscher H. cRNA target preparation for microarrays: comparison of gene expression profiles generated with different amplification procedures. Anal Biochem 2005; 344: 92-101. Pusk\u00e1s LG, Zvara \u00c1, Hackler L Jr, Van Hummelen P. RNA amplification results in reproducible microarray data with slight ratio bias. Biotechniques 2002; 32: 1330-1341). In the present study the number of cancer cells circulating in the blood stream is expected to be extremely small. Therefore, linear RNA amplification (T7 RNA-polymerase) is used in order to generate enough material for labeling and hybridization on the arrays. Two rounds of amplification are performed routinely. This has been performed successfully and reproducibly starting from as little as 700 cells isolated via Laser Capture Microdissection (data unpublished). - Preparation of cell suspension microarrays to isolate circulating cancer cells. Although most of the microarray challenges are known and under control, the present study has an important specific challenge that is the isolation and enrichment of the circulating cancer cells. Currently, the proportion of circulating cancer cells to other nucleated blood cells (leucocytes) is unknown in patients suffering from pancreatic cancer. Therefore, the first step will be to determine the number of cancer cells per ml blood in pancreatic cancer patients and to determine the variability among different patients. A second step is to develop an enrichment method to concentrate the cancer cells without selecting specific types of cancer cells or loss of information on the initial proportion of cancer cells in each patient's blood stream. The fastest way to isolate the circulating cancer cells is using flow cytometry after density-gradient pre-enrichment in combination with negative selection strategies to discard leukocytes (CD45+ and CD34+) from the sorted 'circulating' cancer cells. Isolating cells with LCM has been used many times successfully for microarray studies. It has been reported that LCM can easily dissect several thousands of cells from pancreatic tissue with a RNA-yield of around 1ng/1000 cells (Datson NA, Meijer L, Steenbergen PJ. Morsiak MC, van der Laan S, Meijer OC, de Kloet ER. Expression profiling in laser-microdissected hippocampal subregions in rat brain reveals large subregion specific differences in expression. Eur J Neurosci 2004; 20: 2541-54. Player A, Barrett JC, Kawasaki ES. Laser capture microdissection, microarrays and the precise definition of a cancer cell. Expert Rev Mol Diagn 2004; 4: 831-40. Espina V, Geho D, Mehta AI, Petricoin EF 3rd, Liotta LA, Rosenblatt KP. Pathology of the future: molecular profiling for targeted therapy. Cancer Invest 2005; 23: 36-46. Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, Loader J, Terris B, Stamp G, Baron A, Scarpa A and Lemoine NR. Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 2002; 21: 4587-4594). - Immunological changes Since a tumor type-specific immune reaction in pancreatic cancer or in patients undergoing surgery is lacking, the present study will assess the systemic immunological changes including cytokine levels before and at different time intervals following potentially curative surgery in pancreatic cancer patients. PBMC will be extracted from peripheral venous blood and used for further analysis under FACS (fluorescence-activated cell sorter) to determine the prevalence of: - CD3-19+ (B-lymphocytes) - CD3+56+ (Killer cells) - CD3-56+CD16+ (NK natural killer cells) - CD8+ (Cytotoxic T-lymphocytes) - CD4+25- (Helper T-lymphocytes) - CD4+25+127- (Regulatory T-lymphocytes) - Inflammatory cytokines in peripheral blood (IL-1b, IL-6, IL-8, IL-10, IL-12 and TNF) will be analysed using a commercially available 'BD Cytometric Bead Array (CBA) Human Inflammatory Kit'. - PBMC (peripheral blood mononuclear cells) and tumour tissue will be stored in liquid nitrogen for analysis in future studies. 8. Statistical analysis Univariate analysis as well as corrected, multivariate analysis will be performed in order to identify the optimally combined prognostic group of factors: patient-, tumour-, and treatment-associated factors as well as the amounts of disseminated cancer cells, their genetic expression profile and immunological changes following surgery. The events to study will be cancer recurrence (disease free survival DFS) and death (overall survival OS). 9. Expected patient accrual \"Single center study\": UZ.Gasthuisberg - KU.Leuven, Belgium Expected annual patient registration: 30 pts / year Duration of patient accrual: 2 years", 
    "endDate": "2008-10-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT00495924", 
    "keywords": [
      "prognostic relevance", 
      "cancer cell", 
      "immune suppression", 
      "pancreatic adenocarcinoma", 
      "early recurrence", 
      "curative resection", 
      "dissemination", 
      "manipulation", 
      "alteration", 
      "biological property", 
      "Immune Tolerance", 
      "carcinoma", 
      "commonest", 
      "death", 
      "Neoplasm", 
      "men", 
      "woman", 
      "survival", 
      "stage", 
      "disease", 
      "case-fatality rate", 
      "Pancreatic Neoplasm", 
      "World Health Organization", 
      "world", 
      "Lyon", 
      "press", 
      "patient", 
      "pancreas", 
      "advanced stage", 
      "median survival", 
      "treatment modality", 
      "resection", 
      "curative intent", 
      "cancer recurrence", 
      "Thomas", 
      "Murray", 
      "statistic", 
      "CA", 
      "primary site", 
      "metastatic disease", 
      "liver", 
      "peritoneal cavity", 
      "related factor", 
      "recur", 
      "Jc", 
      "Wang", 
      "Smith", 
      "Hayes", 
      "TG", 
      "HP", 
      "therapy", 
      "Lancet", 
      "General Surgery", 
      "tumor burden", 
      "disseminated cancer", 
      "Carcinogenesis", 
      "immune response", 
      "surgical resection", 
      "proliferation", 
      "cell death", 
      "cancer progression", 
      "Diagnostic Imaging", 
      "molecular technique", 
      "reverse transcriptase-polymerase chain reaction", 
      "RT-PCR", 
      "technique", 
      "sensitive method", 
      "powerful tool", 
      "cancer metastasis", 
      "GV", 
      "LG", 
      "polymerase chain reaction technology", 
      "solid tumor", 
      "Breast Neoplasm", 
      "EpCAM", 
      "epithelial cell adhesion molecule", 
      "independent predictor", 
      "progression-free", 
      "overall survival", 
      "GT", 
      "elli", 
      "Miller", 
      "JM", 
      "Doyle", 
      "tumor cell", 
      "disease progression", 
      "metastatic breast cancer", 
      "N Engl", 
      "marker", 
      "epithelial cell", 
      "adenocarcinoma", 
      "rao", 
      "Russell", 
      "sander", 
      "expression", 
      "carcinoma cell", 
      "blood", 
      "primary and metastatic tumor", 
      "int", 
      "CeA", 
      "K-ras", 
      "pancreatic cancer cell", 
      "Colorectal Neoplasm", 
      "venous blood", 
      "mRNAs", 
      "transcript", 
      "prognostic factor", 
      "Ann", 
      "GC", 
      "single tumor", 
      "quantitative polymerase chain reaction", 
      "molecular characteristic", 
      "metastatic cancer cell", 
      "development", 
      "Neoplasm Metastasis", 
      "selective process", 
      "subpopulation", 
      "metastatic cell", 
      "sequence", 
      "distant metastasis", 
      "complex phenotype", 
      "permanent change", 
      "gene level", 
      "malignant tumor", 
      "cell", 
      "Population Characteristic", 
      "wide range", 
      "growth rate", 
      "status", 
      "cell surface receptor", 
      "product", 
      "enzyme", 
      "karyotype", 
      "cell morphology", 
      "invasiveness", 
      "drug resistance", 
      "specific tumor", 
      "colony", 
      "heterogeneous tumor", 
      "forerunner", 
      "overall efficiency", 
      "metastatic process", 
      "absolute number", 
      "human", 
      "positive relationship", 
      "subsequent development", 
      "experimental study", 
      "fisher", 
      "hepatic metastasis", 
      "homogeneity", 
      "viability", 
      "incidence", 
      "quantitative relationship", 
      "tumor vessel", 
      "pulmonary metastasis", 
      "Cancer Res", 
      "wei", 
      "Holmes", 
      "inefficiency", 
      "mouse", 
      "Experimental Melanoma", 
      "br", 
      "van", 
      "curative surgery", 
      "liver metastasis", 
      "Eur", 
      "poor prognosis", 
      "effective treatment", 
      "effective biomarkers", 
      "early detection", 
      "spreading", 
      "Drug Therapy", 
      "radiation therapy", 
      "molecular basis", 
      "characteristic", 
      "Transcriptome", 
      "important information", 
      "related cancer", 
      "gene profiling", 
      "candidate biomarkers", 
      "gene", 
      "functional aspect", 
      "tumor biology", 
      "pancreatic tumor", 
      "chronic pancreatitis", 
      "pancreatic tissue", 
      "microarrays", 
      "microarray platform", 
      "expressed gene", 
      "platform", 
      "Nielsen", 
      "STAMP", 
      "NR", 
      "expression profiling", 
      "Han", 
      "Rb", 
      "von", 
      "Oligonucleotide Array Sequence Analysis", 
      "NV", 
      "Shen", 
      "Berg", 
      "MA", 
      "Cameron", 
      "Cj", 
      "se", 
      "Rh", 
      "CD", 
      "DM", 
      "tj", 
      "de", 
      "molecular profiling", 
      "multiple gene", 
      "immunological change", 
      "immune system", 
      "feature", 
      "stress response", 
      "natural killer", 
      "lymphocyte", 
      "cell form", 
      "integral component", 
      "tumor surveillance", 
      "immune reaction", 
      "additive effect", 
      "host immune response", 
      "Costa", 
      "Flynn", 
      "laparotomy", 
      "Laparoscopy", 
      "flank", 
      "establishment", 
      "spontaneous tumor", 
      "surgical stress", 
      "temporal pattern", 
      "depression", 
      "Cellular Immunity", 
      "tumor-associated antigen", 
      "delayed type hypersensitivity", 
      "prevalence", 
      "regulatory T cell", 
      "Tregs", 
      "peripheral blood", 
      "tumor microenvironment", 
      "Regulatory T-Lymphocytes", 
      "normal donor", 
      "coexpression", 
      "molecule", 
      "cytokine profile", 
      "infiltrate tumor", 
      "regional lymph node", 
      "CD8+ lymphocyte", 
      "Moore", 
      "M.S", 
      "d.s", 
      "J Immunol", 
      "significance", 
      "dendritic cell", 
      "endpoint", 
      "determinant", 
      "genetic profile", 
      "peri", 
      "Patient Selection", 
      "inclusion criterion", 
      "study intervention", 
      "quantitative analysis", 
      "present study", 
      "start", 
      "central venous catheter", 
      "tissue sample", 
      "biopsy", 
      "intra", 
      "real-time quantitative RT-PCR", 
      "different target", 
      "mRNA transcript", 
      "GUS", 
      "control gene", 
      "blood stream", 
      "copy number", 
      "sample", 
      "duplicate", 
      "RNA extraction", 
      "mini", 
      "company", 
      "sample preparation", 
      "cDNA synthesis", 
      "polymerase chain reaction", 
      "room", 
      "cross-contamination", 
      "genetic profiling", 
      "Messenger RNA", 
      "specific marker", 
      "diagnosis", 
      "drug target", 
      "indication", 
      "gene expression", 
      "bloodstream", 
      "main objective", 
      "expression profile", 
      "different pathway", 
      "tumor suppressor", 
      "oncogene", 
      "signal transduction molecule", 
      "growth factor", 
      "Angiogenesis Inducing Agent", 
      "apoptosis", 
      "cell cycle", 
      "cell growth", 
      "Cell Movement", 
      "motility", 
      "signal transduction", 
      "cancer-related gene", 
      "microarray technology", 
      "manufacturing", 
      "complete genome", 
      "amplification", 
      "small sample", 
      "total RNA", 
      "CC", 
      "Chen", 
      "OA", 
      "MJ", 
      "generation", 
      "small number", 
      "microarray study", 
      "preparation", 
      "comparison", 
      "anal", 
      "Jr", 
      "RNA amplification", 
      "microarray data", 
      "ratio", 
      "T7 RNA", 
      "labeling", 
      "hybridization", 
      "array", 
      "round", 
      "laser capture microdissection", 
      "cell suspension", 
      "control", 
      "specific Challenge", 
      "isolation", 
      "enrichment", 
      "proportion", 
      "blood cell", 
      "leucocyte", 
      "first step", 
      "pancreatic cancer patient", 
      "variability", 
      "different patient", 
      "second step", 
      "specific type", 
      "fast way", 
      "flow cytometry", 
      "density gradient", 
      "negative selection", 
      "leukocyte", 
      "Isolating", 
      "LCM", 
      "yield", 
      "Na", 
      "MC", 
      "van der", 
      "OC", 
      "ER", 
      "hippocampal subregions", 
      "rat brain", 
      "specific difference", 
      "player", 
      "Barrett", 
      "ES", 
      "laser", 
      "microdissection", 
      "precise definition", 
      "expert", 
      "EF", 
      "LA", 
      "KP", 
      "pathology", 
      "targeted therapy", 
      "cytokine level", 
      "different time interval", 
      "PBMC", 
      "FACS", 
      "fluorescence activated cell sorter", 
      "CD3", 
      "B-Lymphocytes", 
      "killer cell", 
      "Natural Killer Cell", 
      "cytotoxic T lymphocyte", 
      "Helper-Inducer T-Lymphocytes", 
      "inflammatory cytokine", 
      "IL-1b", 
      "Interleukin-6", 
      "Interleukin-8", 
      "Interleukin-10", 
      "TNF", 
      "BD", 
      "peripheral blood mononuclear cell", 
      "tumor tissue", 
      "liquid nitrogen", 
      "future study", 
      "statistical analysis", 
      "multivariate analysis", 
      "prognostic group", 
      "associated factor", 
      "genetic expression", 
      "Disease-Free Survival", 
      "single-center study", 
      "registration", 
      "Pt", 
      "duration", 
      "patient accrual"
    ], 
    "name": "Prognostic Relevance of Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT00495924"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00004.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.8668.0", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.434261.6", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.5596.f", 
        "type": "Organization"
      }
    ], 
    "startDate": "2006-10-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1186/1471-2407-12-527", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002024395", 
          "https://doi.org/10.1186/1471-2407-12-527"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2407-11-47", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040019711", 
          "https://doi.org/10.1186/1471-2407-11-47"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT00495924"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00495924'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00495924'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00495924'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00495924'


 

This table displays all metadata directly associated to this object as RDF triples.

445 TRIPLES      16 PREDICATES      431 URIs      420 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT00495924 schema:about anzsrc-for:3103
2 anzsrc-for:3142
3 schema:description The purpose of this study is to determine whether early recurrence after curative resection of ductal pancreatic adenocarcinoma can be explained by either dissemination of cancer cells during intraoperative tumour manipulation, post-operative systemic immune suppression, alteration of biological properties of circulating cancer cells or a combination of these. Detailed Description Prognostic relevance of circulating cancer cells and immunosuppression in resectable pancreatic carcinoma 1. Introduction Pancreatic adenocarcinoma is the fourth commonest cause of death from cancer in men and women, with 5-year survival for all stages of disease of less than 5%. The case-fatality rate for pancreatic cancer is extremely high and virtually identical to the number of new cases (World Health Organization. World cancer report. Lyon: IACR Press; 2003). Most patients with cancer of the pancreas are diagnosed at an advanced stage and have a median survival of 4 to 10 months, depending on the extent of disease and irrespective the type of treatment modality. Overall, fewer than 5% of the patients have resection with curative intent, though over 80% will develop cancer recurrence (Jemal A, Thomas A, Murray T, Thun M. Cancer Statistics. CA Cancer J Clin 2002; 52: 23-47). The primary site of metastatic disease in patients with pancreatic cancer is the liver and/or the peritoneal cavity. Cancer recurrence is multifactorial and determined by patient-, tumour-, and surgery-related factors. Any combination of several mechanisms have been proposed by which cancer may recur following potentially curative resection (Coffey JC, Wang JH, Smith MJF, Bouchier-Hayes D, Cotter TG,and Redmond HP. Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol 2003;4:760-68). Surgery may contribute to the overall residual tumor burden by adding disseminated cancer cells during tumor manipulation. Due to post-operative immunosuppression the patient may become more susceptible to tumorigenesis and/or disseminated cancer cells may escape the immune response more easily. Finally, surgical resection may alter biological properties of cancer cells and lead to increased cellular proliferation and reduced cell death. 2. Cancer cell dissemination Solid markers are lacking to predict cancer recurrence or cancer progression before being measurable with conventional or modern diagnostic imaging. Molecular techniques such as the reverse transcriptase polymerase chain reaction (RT-PCR) technique have proven to be a highly sensitive method and a powerful tool in the study of cancer metastasis (Raj GV, Moreno JG, Gomella LG. Utilization of Polymerase Chain Reaction Technology in the Detection of Solid Tumors. Cancer 1998; 82: 1419-42). The prognostic relevance of circulating cancer cells in patients with pancreatic cancer is hardly studied. In patients with breast cancer the number of circulating cancer cells expressing EpCAM (epithelial cell adhesion molecule) has proven to be an independent predictor of progression-free and overall survival (Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-91). EpCAM is a marker present on most epithelial cell tumours and frequently overexpressed in primary and metastatic adenocarcinoma including pancreatic cancer (Rao CG, Chianese D, Doyle GV, Miller MC, Russell T, Sanders RA Jr, Terstappen LW. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol 2005; 27: 49-57). Also, other markers such as CEA, CK20, K-ras have been used to detect disseminated pancreatic cancer cells. In patients with colorectal carcinoma circulating cancer cells in peripheral or in mesenteric venous blood as detected by RT-PCR, using CEA and CK20 mRNA transcripts, seem to represent a prognostic factor (Yamaguchi K, Takagi Y, Aoki S, Futamura M, Saji S. Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann Surg 2000; 232: 58-65. Guller U, Zajac P, Schnider A, Bösch B, Vorburger S, Zuber M, Spagnoli GC, Oertli D, Maurer R, Metzger U, Harder F, Heberer M, Marti WR. Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg 2002; 236: 768-76). 3. Molecular characteristics of metastatic cancer cells The development of metastasis is a highly selective process favoring the survival of a minor subpopulation of metastatic cells. To produce metastases, tumor cells from this subpopulation must complete a sequence of interrelated steps. To produce clinically relevant distant metastases, the successful metastatic cell must therefore exhibit a complex phenotype that is regulated by transient or permanent changes at the gene level. Many malignant tumors, including pancreatic cancer, contain heterogeneous subpopulations of cells. This heterogeneity is exhibited in a wide range of genetic, biochemical, immunological, and biological characteristics such as growth rate, antigenic and immunogenic status, cell surface receptors and products, enzymes, karyotypes, cell morphologies, invasiveness, drug resistance, and metastatic potential. It is likely that specific tumor cells or colonies within the larger heterogeneous tumor specimen are the forerunners of distant metastases. The overall efficiency of the whole metastatic process itself is low. Although the absolute number of cancer cells required for metastasis in humans is unknown, a positive relationship between the number of circulating cancer cells and the subsequent development of metastases has been the subject of several experimental studies (Fisher, E.R. and Fisher, B. Experimental study of factors influencing development of hepatic metastases from circulating tumor cells. Acta Cytol. 9: 146-159, 1965. Fidler, I.J. The relationship of embolic homogeneity, number, size and viability to the incidence of experimental metastasis. Europ. J. Cancer 9: 223-227, 1973. Liotta, L.A., Kleinerman, J., Saidel, G. Quantitative relationships of intravascular tumor cells, tumor vessels and pulmonary metastasis. Cancer Res. 34: 977-1004, 1974. Weiss, L., Mayhew, E., Glaves, R.P. and Holmes, J.C. Metastatic inefficiency in mice bearing B16 melanomas. Br. J. Cancer 45: 44-53, 1982. Topal B, Aerts JL, Roskams T, Fieuws S, Van Pelt J, Vandekerckhove P, Penninckx F. Cancer cell dissemination during curative surgery for colorectal liver metastases. Eur J Surg Oncol 2005; 31: 506-511). The poor prognosis and lack of effective treatments for pancreatic cancer arise from several causes. There are currently no effective biomarkers useful for early detection of pancreatic cancer that tends to rapidly invade surrounding structures and undergo early metastatic spreading. Moreover, pancreatic cancer is highly resistant to both chemotherapy and radiation therapy. Currently, the molecular basis for these characteristics is unknown. Gene expression profiles provide important information about the molecular characteristics of the cancers and can be used to distinguish closely related cancer subtypes. Gene profiling can also be used to develop candidate biomarkers and to identify groups of genes involved in specific functional aspects of tumor biology. Gene expression profiles that could distinguish between pancreatic tumors, chronic pancreatitis and normal pancreatic tissue have been studied extensively using different microarrays and microarray platforms. The differentially expressed genes in pancreatic tumor tissues were found to be quite specific and highly reproducible among platforms and studies (Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, Loader J, Terris B, Stamp G, Baron A, Scarpa A and Lemoine NR. Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 2002; 21: 4587-4594. Han H, Bearss DJ, Browne LW, Calaluce R, Naagle RB, Von Hoff DD. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 2002; 62: 2890-96. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, Adsay NV, Shen-Ong GL, Berg K, Hollingsworth MA, Cameron JL, Yeo CJ, Kern SE, Goggins M, Hruban RH. Cancer Res 2003; 63: 8614-22. Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, Misek DE, Hanash S. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 2003; 63: 2649-57). 4. Peri-operative immunological changes Suppression of the immune system is a feature of the post-operative stress response, in which natural killer (NK) and lymphocyte activated killer (LAK) cells form an integral component in immune anti-tumor surveillance. However, a tumor type-specific immune reaction in pancreatic cancer or in patients undergoing surgery is lacking. Anti-tumoral activities of NK and LAK cells are reduced immediately after surgery so the additive effects of surgery may be sufficient to improve the ability of disseminated cancer cells to evade the host immune response long enough for metastases to develop (Da Costa ML, Finnegan N, Flynn M, Bouchier-Hayes DJ. Laparotomy and laparoscopy differentially accelerate experimental flank tumourgrowth. Br J Surg 1998; 85: 1439-42.) (Da Costa ML, Redmond HP, Bouchier-Hayes DJ. The effect of laparotomy and laparoscopy on the establishment of spontaneous tumour metastases. Surgery 1998; 124: 516-26). The suppressive immunological changes that follow surgical stress occur along a temporal pattern. Depression of cellular immunity to tumor-associated antigen and depression of delayed-type hypersensitivity are present for up to 3 weeks after surgery. In patients with pancreatic cancer the prevalence of regulatory T cells (Treg) is increased in the peripheral blood as well as in the tumour microenvironment. These Treg cells (CD4+25+) are phenotypically similar to Treg cells from normal donors by coexpression of CD45R0 and CTLA-4 molecules as well as cytokine profile. Regulatory CD4+25+ lymphocytes infiltrate tumor and regional lymph nodes, and suppress activation of CD8+ lymphocytes and helper CD4+25- lymphocytes (Liyanage, U. K., T. T. Moore, H. G. Joo, Y. Tanaka, V. Herrmann, G. Doherty, J. A. Drebin, S. M. Strasberg, T. J. Eberlein, P. S. Goedegebuure, and D. C. Linehan. 2002. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756). However, the oncological significance of changes in activities and numbers of NK, LAK, Treg and dendritic cells still has to be confirmed. 5. Aims / Endpoints - Is the number of circulating cancer cells a determinant for cancer recurrence and/or survival following potentially curative resection of pancreatic cancer? - Is the genetic profile of circulating cancer cells a determinant for cancer recurrence and/or survival following potentially curative resection of pancreatic cancer? - Is peri-operative immunosuppression correlated with cancer recurrence and/or survival following potentially curative resection of pancreatic cancer? 6. Patient selection and inclusion criteria: Potentially curable/ resectable pancreatic cancer 7. Study interventions - Quantitative analysis of circulating cancer cells In the present study peripheral venous blood samples will be obtained before the start of surgery, at the end of surgery, on the first day after and on day 7 after surgery through a central venous catheter. Tumour tissue samples and random liver tru-cut biopsies will be obtained intra-operatively. Real-time quantitative RT-PCR technique (TaqManR), based on 3 different target markers (CEA, CK20 and EpCAM mRNA transcripts) and beta-glucuronidase (GUS) as control gene, will be used to detect and quantify circulating cancer cells in the blood stream. Normalized copy numbers (NCN) will be determined in each sample (analyzed in duplicate). RNA extraction from all samples will be performed using RNeasy mini kit(Qiagen, BD Company). Sample preparation, cDNA synthesis and PCR will be performed in separated rooms in order to prevent cross-contamination. - Genetic profiling of disseminated cancer cells Oligonucleotide microarray analysis of mRNA extracted from the primary pancreatic tumor and from disseminated cancer cells before, during and the day after surgery. The focus of this study is not to identify specific markers for diagnosis or for drug targets but to find indications of metastasis through the study of gene expression in cancer cells circulating in the bloodstream. Our main objective is to analyze expression profiles of circulating pancreatic cancer cells. Changes will be analyzed in the expression of genes representative of several different pathways frequently altered during the progression of cancer such as tumor suppressors, oncogenes, signal transduction molecules, growth factors and angiogenesis factors. Gene expression profile data will be obtained on apoptosis, cell cycle, cell growth and differentiation, cell migration and motility, signal transduction and other cancer-related genes. Latest developments in microarray technology comprise the manufacturing of the complete genome and in designing new amplification strategies to be able to analyze very small samples less than 1 ng total RNA (Xiang CC, Chen M, Kozhich OA, Phan QN, Inman JM, Chen Y, Brownstein MJ. Probe generation directly from small number of cells for DNA microarray studies. Biotechniques 2003; 34: 386-8, 390, 392-3. Schindler H, Wiese A, Auer J, Burtscher H. cRNA target preparation for microarrays: comparison of gene expression profiles generated with different amplification procedures. Anal Biochem 2005; 344: 92-101. Puskás LG, Zvara Á, Hackler L Jr, Van Hummelen P. RNA amplification results in reproducible microarray data with slight ratio bias. Biotechniques 2002; 32: 1330-1341). In the present study the number of cancer cells circulating in the blood stream is expected to be extremely small. Therefore, linear RNA amplification (T7 RNA-polymerase) is used in order to generate enough material for labeling and hybridization on the arrays. Two rounds of amplification are performed routinely. This has been performed successfully and reproducibly starting from as little as 700 cells isolated via Laser Capture Microdissection (data unpublished). - Preparation of cell suspension microarrays to isolate circulating cancer cells. Although most of the microarray challenges are known and under control, the present study has an important specific challenge that is the isolation and enrichment of the circulating cancer cells. Currently, the proportion of circulating cancer cells to other nucleated blood cells (leucocytes) is unknown in patients suffering from pancreatic cancer. Therefore, the first step will be to determine the number of cancer cells per ml blood in pancreatic cancer patients and to determine the variability among different patients. A second step is to develop an enrichment method to concentrate the cancer cells without selecting specific types of cancer cells or loss of information on the initial proportion of cancer cells in each patient's blood stream. The fastest way to isolate the circulating cancer cells is using flow cytometry after density-gradient pre-enrichment in combination with negative selection strategies to discard leukocytes (CD45+ and CD34+) from the sorted 'circulating' cancer cells. Isolating cells with LCM has been used many times successfully for microarray studies. It has been reported that LCM can easily dissect several thousands of cells from pancreatic tissue with a RNA-yield of around 1ng/1000 cells (Datson NA, Meijer L, Steenbergen PJ. Morsiak MC, van der Laan S, Meijer OC, de Kloet ER. Expression profiling in laser-microdissected hippocampal subregions in rat brain reveals large subregion specific differences in expression. Eur J Neurosci 2004; 20: 2541-54. Player A, Barrett JC, Kawasaki ES. Laser capture microdissection, microarrays and the precise definition of a cancer cell. Expert Rev Mol Diagn 2004; 4: 831-40. Espina V, Geho D, Mehta AI, Petricoin EF 3rd, Liotta LA, Rosenblatt KP. Pathology of the future: molecular profiling for targeted therapy. Cancer Invest 2005; 23: 36-46. Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, Loader J, Terris B, Stamp G, Baron A, Scarpa A and Lemoine NR. Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 2002; 21: 4587-4594). - Immunological changes Since a tumor type-specific immune reaction in pancreatic cancer or in patients undergoing surgery is lacking, the present study will assess the systemic immunological changes including cytokine levels before and at different time intervals following potentially curative surgery in pancreatic cancer patients. PBMC will be extracted from peripheral venous blood and used for further analysis under FACS (fluorescence-activated cell sorter) to determine the prevalence of: - CD3-19+ (B-lymphocytes) - CD3+56+ (Killer cells) - CD3-56+CD16+ (NK natural killer cells) - CD8+ (Cytotoxic T-lymphocytes) - CD4+25- (Helper T-lymphocytes) - CD4+25+127- (Regulatory T-lymphocytes) - Inflammatory cytokines in peripheral blood (IL-1b, IL-6, IL-8, IL-10, IL-12 and TNF) will be analysed using a commercially available 'BD Cytometric Bead Array (CBA) Human Inflammatory Kit'. - PBMC (peripheral blood mononuclear cells) and tumour tissue will be stored in liquid nitrogen for analysis in future studies. 8. Statistical analysis Univariate analysis as well as corrected, multivariate analysis will be performed in order to identify the optimally combined prognostic group of factors: patient-, tumour-, and treatment-associated factors as well as the amounts of disseminated cancer cells, their genetic expression profile and immunological changes following surgery. The events to study will be cancer recurrence (disease free survival DFS) and death (overall survival OS). 9. Expected patient accrual "Single center study": UZ.Gasthuisberg - KU.Leuven, Belgium Expected annual patient registration: 30 pts / year Duration of patient accrual: 2 years
4 schema:endDate 2008-10-01T00:00:00Z
5 schema:keywords Angiogenesis Inducing Agent
6 Ann
7 B-Lymphocytes
8 BD
9 Barrett
10 Berg
11 Breast Neoplasm
12 CA
13 CC
14 CD
15 CD3
16 CD8+ lymphocyte
17 Cameron
18 Cancer Res
19 Carcinogenesis
20 CeA
21 Cell Movement
22 Cellular Immunity
23 Chen
24 Cj
25 Colorectal Neoplasm
26 Costa
27 DM
28 Diagnostic Imaging
29 Disease-Free Survival
30 Doyle
31 Drug Therapy
32 EF
33 ER
34 ES
35 EpCAM
36 Eur
37 Experimental Melanoma
38 FACS
39 Flynn
40 GC
41 GT
42 GUS
43 GV
44 General Surgery
45 HP
46 Han
47 Hayes
48 Helper-Inducer T-Lymphocytes
49 Holmes
50 IL-1b
51 Immune Tolerance
52 Interleukin-10
53 Interleukin-6
54 Interleukin-8
55 Isolating
56 J Immunol
57 JM
58 Jc
59 Jr
60 K-ras
61 KP
62 LA
63 LCM
64 LG
65 Lancet
66 Laparoscopy
67 Lyon
68 M.S
69 MA
70 MC
71 MJ
72 Messenger RNA
73 Miller
74 Moore
75 Murray
76 N Engl
77 NR
78 NV
79 Na
80 Natural Killer Cell
81 Neoplasm
82 Neoplasm Metastasis
83 Nielsen
84 OA
85 OC
86 Oligonucleotide Array Sequence Analysis
87 PBMC
88 Pancreatic Neoplasm
89 Patient Selection
90 Population Characteristic
91 Pt
92 RNA amplification
93 RNA extraction
94 RT-PCR
95 Rb
96 Regulatory T-Lymphocytes
97 Rh
98 Russell
99 STAMP
100 Shen
101 Smith
102 T7 RNA
103 TG
104 TNF
105 Thomas
106 Transcriptome
107 Tregs
108 Wang
109 World Health Organization
110 absolute number
111 additive effect
112 adenocarcinoma
113 advanced stage
114 alteration
115 amplification
116 anal
117 apoptosis
118 array
119 associated factor
120 biological property
121 biopsy
122 blood
123 blood cell
124 blood stream
125 bloodstream
126 br
127 cDNA synthesis
128 cancer cell
129 cancer metastasis
130 cancer progression
131 cancer recurrence
132 cancer-related gene
133 candidate biomarkers
134 carcinoma
135 carcinoma cell
136 case-fatality rate
137 cell
138 cell cycle
139 cell death
140 cell form
141 cell growth
142 cell morphology
143 cell surface receptor
144 cell suspension
145 central venous catheter
146 characteristic
147 chronic pancreatitis
148 coexpression
149 colony
150 commonest
151 company
152 comparison
153 complete genome
154 complex phenotype
155 control
156 control gene
157 copy number
158 cross-contamination
159 curative intent
160 curative resection
161 curative surgery
162 cytokine level
163 cytokine profile
164 cytotoxic T lymphocyte
165 d.s
166 de
167 death
168 delayed type hypersensitivity
169 dendritic cell
170 density gradient
171 depression
172 determinant
173 development
174 diagnosis
175 different pathway
176 different patient
177 different target
178 different time interval
179 disease
180 disease progression
181 disseminated cancer
182 dissemination
183 distant metastasis
184 drug resistance
185 drug target
186 duplicate
187 duration
188 early detection
189 early recurrence
190 effective biomarkers
191 effective treatment
192 elli
193 endpoint
194 enrichment
195 enzyme
196 epithelial cell
197 epithelial cell adhesion molecule
198 establishment
199 experimental study
200 expert
201 expressed gene
202 expression
203 expression profile
204 expression profiling
205 fast way
206 feature
207 first step
208 fisher
209 flank
210 flow cytometry
211 fluorescence activated cell sorter
212 forerunner
213 functional aspect
214 future study
215 gene
216 gene expression
217 gene level
218 gene profiling
219 generation
220 genetic expression
221 genetic profile
222 genetic profiling
223 growth factor
224 growth rate
225 hepatic metastasis
226 heterogeneous tumor
227 hippocampal subregions
228 homogeneity
229 host immune response
230 human
231 hybridization
232 immune reaction
233 immune response
234 immune suppression
235 immune system
236 immunological change
237 important information
238 incidence
239 inclusion criterion
240 independent predictor
241 indication
242 inefficiency
243 infiltrate tumor
244 inflammatory cytokine
245 int
246 integral component
247 intra
248 invasiveness
249 isolation
250 karyotype
251 killer cell
252 labeling
253 laparotomy
254 laser
255 laser capture microdissection
256 leucocyte
257 leukocyte
258 liquid nitrogen
259 liver
260 liver metastasis
261 lymphocyte
262 mRNA transcript
263 mRNAs
264 main objective
265 malignant tumor
266 manipulation
267 manufacturing
268 marker
269 median survival
270 men
271 metastatic breast cancer
272 metastatic cancer cell
273 metastatic cell
274 metastatic disease
275 metastatic process
276 microarray data
277 microarray platform
278 microarray study
279 microarray technology
280 microarrays
281 microdissection
282 mini
283 molecular basis
284 molecular characteristic
285 molecular profiling
286 molecular technique
287 molecule
288 motility
289 mouse
290 multiple gene
291 multivariate analysis
292 natural killer
293 negative selection
294 normal donor
295 oncogene
296 overall efficiency
297 overall survival
298 pancreas
299 pancreatic adenocarcinoma
300 pancreatic cancer cell
301 pancreatic cancer patient
302 pancreatic tissue
303 pancreatic tumor
304 pathology
305 patient
306 patient accrual
307 peri
308 peripheral blood
309 peripheral blood mononuclear cell
310 peritoneal cavity
311 permanent change
312 platform
313 player
314 polymerase chain reaction
315 polymerase chain reaction technology
316 poor prognosis
317 positive relationship
318 powerful tool
319 precise definition
320 preparation
321 present study
322 press
323 prevalence
324 primary and metastatic tumor
325 primary site
326 product
327 prognostic factor
328 prognostic group
329 prognostic relevance
330 progression-free
331 proliferation
332 proportion
333 pulmonary metastasis
334 quantitative analysis
335 quantitative polymerase chain reaction
336 quantitative relationship
337 radiation therapy
338 rao
339 rat brain
340 ratio
341 real-time quantitative RT-PCR
342 recur
343 regional lymph node
344 registration
345 regulatory T cell
346 related cancer
347 related factor
348 resection
349 reverse transcriptase-polymerase chain reaction
350 room
351 round
352 sample
353 sample preparation
354 sander
355 se
356 second step
357 selective process
358 sensitive method
359 sequence
360 signal transduction
361 signal transduction molecule
362 significance
363 single tumor
364 single-center study
365 small number
366 small sample
367 solid tumor
368 specific Challenge
369 specific difference
370 specific marker
371 specific tumor
372 specific type
373 spontaneous tumor
374 spreading
375 stage
376 start
377 statistic
378 statistical analysis
379 status
380 stress response
381 study intervention
382 subpopulation
383 subsequent development
384 surgical resection
385 surgical stress
386 survival
387 targeted therapy
388 technique
389 temporal pattern
390 therapy
391 tissue sample
392 tj
393 total RNA
394 transcript
395 treatment modality
396 tumor biology
397 tumor burden
398 tumor cell
399 tumor microenvironment
400 tumor suppressor
401 tumor surveillance
402 tumor tissue
403 tumor vessel
404 tumor-associated antigen
405 van
406 van der
407 variability
408 venous blood
409 viability
410 von
411 wei
412 wide range
413 woman
414 world
415 yield
416 schema:name Prognostic Relevance of Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma
417 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00495924
418 schema:sdDatePublished 2019-03-07T15:22
419 schema:sdLicense https://scigraph.springernature.com/explorer/license/
420 schema:sdPublisher Nade6155cb1fd4a45b019fa8c40083bc0
421 schema:sponsor https://www.grid.ac/institutes/grid.434261.6
422 https://www.grid.ac/institutes/grid.5596.f
423 https://www.grid.ac/institutes/grid.8668.0
424 schema:startDate 2006-10-01T00:00:00Z
425 schema:subjectOf sg:pub.10.1186/1471-2407-11-47
426 sg:pub.10.1186/1471-2407-12-527
427 schema:url https://clinicaltrials.gov/show/NCT00495924
428 sgo:license sg:explorer/license/
429 sgo:sdDataset clinical_trials
430 rdf:type schema:MedicalStudy
431 Nade6155cb1fd4a45b019fa8c40083bc0 schema:name Springer Nature - SN SciGraph project
432 rdf:type schema:Organization
433 anzsrc-for:3103 schema:inDefinedTermSet anzsrc-for:
434 rdf:type schema:DefinedTerm
435 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
436 rdf:type schema:DefinedTerm
437 sg:pub.10.1186/1471-2407-11-47 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040019711
438 https://doi.org/10.1186/1471-2407-11-47
439 rdf:type schema:CreativeWork
440 sg:pub.10.1186/1471-2407-12-527 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002024395
441 https://doi.org/10.1186/1471-2407-12-527
442 rdf:type schema:CreativeWork
443 https://www.grid.ac/institutes/grid.434261.6 schema:Organization
444 https://www.grid.ac/institutes/grid.5596.f schema:Organization
445 https://www.grid.ac/institutes/grid.8668.0 schema:Organization
 




Preview window. Press ESC to close (or click here)


...